Howard-Stone Rye, Gerwin Philip, Capunitan Darien, Driscoll Mark, Jackson Eric, Tran Thi Dong Binh, Măndoiu Ion, Oziolor Elias
School of Computing, University of Connecticut, Storrs, CT, United States.
Pfizer, Groton, CT, United States.
Front Microbiol. 2025 Aug 11;16:1632210. doi: 10.3389/fmicb.2025.1632210. eCollection 2025.
Translation of nonclinical findings from laboratory mice to the clinic may be confounded by un-controlled variance in bacterial gut content, as a driver of immune maturation and recruitment, as well as drug metabolism. Understanding and controlling for microbiome variation in animal experiments can lead to better reproducibility of animal findings, more translatable characterization of efficacy and toxicity end-points and time and cost savings associated with pharmaceutical development. Microbiome composition has been linked to failure of translation of drug responses.
In an effort to test the stability of microbiome introduction, we compare various methods for establishing a well-characterized, stable bacterial community in laboratory mice via Cecal Microbiome Transplant (CMT) with and without antibiotic preconditioning.
We demonstrate a single CMT treatment protocol effectively treats outbred mouse populations with two different initial gut bacterial profiles, causing the populations to converge to a third, more wild-type bacterial genetic environment suitable for initiation of nonclinical studies. We show that ASV-based monitoring provides the highest resolution for identifying and tracking bacterial profile differences, which can be obscured at the species level. We find that antibiotic preconditioning reduces efficiency for uptake of CMT-specific strains. Instead, antibiotics introduce uncontrolled variance in the resulting microbiome composition.
We propose that CMT without antibiotic preconditioning provides increased control over host microbial composition, enabling expanded utility, accuracy, and relevance for nonclinical drug toxicity and therapeutic effect studies in laboratory mice, with minimal additional costs.
从实验室小鼠到临床的非临床研究结果的转化可能会因肠道细菌含量的不受控制的差异而受到混淆,肠道细菌含量是免疫成熟和募集以及药物代谢的驱动因素。在动物实验中了解和控制微生物组变异可提高动物研究结果的可重复性,使疗效和毒性终点的特征更具可转化性,并节省与药物开发相关的时间和成本。微生物组组成与药物反应转化失败有关。
为了测试微生物组引入的稳定性,我们比较了通过盲肠微生物组移植(CMT)在实验室小鼠中建立特征明确、稳定的细菌群落的各种方法,有无抗生素预处理。
我们证明了单一的CMT治疗方案有效地治疗了具有两种不同初始肠道细菌谱的远交系小鼠群体,使这些群体收敛到第三种更适合启动非临床研究的野生型细菌遗传环境。我们表明,基于ASV的监测为识别和跟踪细菌谱差异提供了最高分辨率,而这些差异在物种水平上可能会被掩盖。我们发现抗生素预处理会降低CMT特异性菌株的摄取效率。相反,抗生素会在所得微生物组组成中引入不受控制的差异。
我们提出,不进行抗生素预处理的CMT能更好地控制宿主微生物组成,从而扩大其在实验室小鼠非临床药物毒性和治疗效果研究中的效用、准确性和相关性,且成本增加极少。